share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股SEC公告 ·  08/22 01:22
牛牛AI助理已提取核心訊息
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation，一家醫療技術公司，已與H.C. Wainwright & Co.，LLC於2024年8月20日簽訂了一份按市場價格發行協議。根據該協議，SeaStar醫療公司可以不時地通過Wainwright出售高達2500萬美元的普通股。這些股票可以在納斯達克資本市場或美國其他現有交易市場上進行交易。Wainwright將充當銷售代理，並努力以商業合理方式代表SeaStar醫療公司出售股票。該發行將在SeaStar醫療公司或Wainwright任一方解除協議時終止。此舉是在SeaStar醫療公司最近的進展之後，包括獲得FDA對其用於兒科使用的選擇性細胞浸潤裝置(SCD)的可批准信函，以及在成人急性腎損傷患者中啓動SCD的關鍵試驗。公司的普通股和認股權證分別在納斯達克上交易，股票代碼分別爲「ICU」和「ICUCW」。
SeaStar Medical Holding Corporation，一家醫療技術公司，已與H.C. Wainwright & Co.，LLC於2024年8月20日簽訂了一份按市場價格發行協議。根據該協議，SeaStar醫療公司可以不時地通過Wainwright出售高達2500萬美元的普通股。這些股票可以在納斯達克資本市場或美國其他現有交易市場上進行交易。Wainwright將充當銷售代理，並努力以商業合理方式代表SeaStar醫療公司出售股票。該發行將在SeaStar醫療公司或Wainwright任一方解除協議時終止。此舉是在SeaStar醫療公司最近的進展之後，包括獲得FDA對其用於兒科使用的選擇性細胞浸潤裝置(SCD)的可批准信函，以及在成人急性腎損傷患者中啓動SCD的關鍵試驗。公司的普通股和認股權證分別在納斯達克上交易，股票代碼分別爲「ICU」和「ICUCW」。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。